Contrast Echocardiography in Non-ST Elevation Myocardial Infarction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01122069|
Recruitment Status : Completed
First Posted : May 12, 2010
Last Update Posted : May 12, 2010
In patients with acute myocardial infarction, treatment logistics are primarily defined based upon ST segment shift in the electrocardiogram. While patients with ST elevation (STEMI) are forwarded to immediate coronary angiography and percutaneous coronary intervention, patients without ST elevation (NSTEMI) are initially medically treated and recommended coronary angiography within 48-72 hours.
Early invasive treatment has been found cost-effective in intermediate and high-risk NSTEMI patients and current guidelines recommend use of the Thrombolysis in Myocardial Infarction (TIMI) risk score to identify patients who will benefit from early intervention due to high risk of new infraction and cardiovascular death. However, new research has suggested that TIMI risk score may not always identify patients with severe angiographic disease.
The purpose of this study was to assess if contrast echocardiography could be used to identify NSTEMI patients with angiographically severe disease independent of their TIMI risk score.
|Condition or disease||Intervention/treatment|
|Non-ST-Elevation Myocardial Infarction||Other: Perflutren Lipid Microsphere ultrasound contrast|
|Study Type :||Observational|
|Actual Enrollment :||110 participants|
|Official Title:||Contrast Echocardiography in Assessment of Myocardial Perfusion in Patients With Non-ST Elevation Myocardial Infarction|
|Study Start Date :||March 2008|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||July 2009|
110 patients with acute non-ST elevation myocardial infarct were examined with contrast echocardiography prior to coronary angiography.
Other: Perflutren Lipid Microsphere ultrasound contrast
Perflutren Lipid Microsphere ultrasound contrast 0.01 ml/kg administered as intravenous bolus
Other Name: Luminity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01122069
|Department of Heart Disease, Haukeland University Hospital|
|Principal Investigator:||Mai Tone Lønnebakken, MD||University of Bergen, Bergen, Norway|